| Name | dCBP-1 |
| Description | dCBP-1 is a chemical degrader of p300/CBP. dCBP-1 hijacks the E3 ubiquitin ligase CRBN for selective degradation of p300/CBP. Degradation of p300/CBP by dCBP-1 leads to effective multiple myeloma cell killing. |
| In vitro | Treatment of the human haploid cell line HAP1 for 6 h with dCBP-1 revealed almost complete loss of both CBP and p300 between 10 and 1,000 nM doses. A time course analysis with 250 nM dCBP-1 revealed almost complete degradation of p300/CBP within an hour of treatment[1]. dCBP-1 was also able to induce near-complete p300/CBP degradation across other multiple myeloma cell lines tested, including MM1R, KMS-12-BM, and KMS34[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (48.63 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (1.95 mM), Sonication is recommended.
|
| Keywords | PROTACs | p300 | myeloma | MYC | multiple | Inhibitor | inhibit | heterobifunctional | EpigeneticReaderDomain | Epigenetic Reader Domain | degrader | dCBP-1 | dCBP1 | dCBP 1 | CRBN | Cereblon | cell | CBP/p300 | CBP |
| Inhibitors Related | ABBV-744 | SNDX-5613 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | J-147 | 5-Ph-IAA | Bavdegalutamide | Curcumin | Naphthol AS-E | Vepdegestrant | JQ-1 (carboxylic acid) | Bisdemethoxycurcumin |
| Related Compound Libraries | Histone Modification Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Multi-Target Compound Library | Post-Translational Modification Compound Library | PPI Inhibitor Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library |